Posted by Michael Wonder on 09 Mar 2024
Fresenius Kabi’s biosimilar Tyenne (tocilizumab-aazg) becomes the first intravenous and subcutaneous tocilizumab biosimilar approved by the FDA
7 March 2024 - Fresenius Kabi announced today that the US FDA has approved Tyenne (tocilizumab-aazg), its tocilizumab biosimilar referencing Actemra (tocilizumab).
Tyenne becomes the first tocilizumab biosimilar with both intravenous and subcutaneous formulations approved by the FDA.
